OBJECTIVE To compare the cost-effectiveness of three treatment regimens using recombinant activated Factor VII (rFVIIa), NovoSeven, and activated prothrombin-complex concentrate (APCC), FEIBA VH, for home treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. METHODS A literature-based, decision-analytic model was developed to compare three treatment regimens. The regim...

Hemophilia A and B are severe Xlinked inherited bleeding disorders caused by deficiency of blood coagulation factors (F) VIII and FIX, respectively. Currently, hemophilia is treated with protein replacement therapy using either plasma-derived or recombinant coagulation factors. Although replacement therapy is extremely effective and has significantly enhanced the quality and life expectancy of ...

An important question with regard to the treatment of cancer patients with chemotherapy is whether recombinant thrombopoietin (rhTPO) can improve the platelet count and shorten the period of thrombocytopenia induced by chemotherapy. Both full-length rhTPO and a truncated version of the molecule, known as peggylated recombinant human megakaryocyte growth and development factor, have been evaluat...

The activity of coagulation factor VIII (FVIII:C) is reported to be between 5 and 40% in patients with mild haemophilia A (HA) [1]. This disease is often diagnosed in adulthood due to bleeding episodes after trauma or surgery that require replacement therapy with FVIII concentrates (FVIIIc). Although FVIII inhibitors develop less frequently in mild HA patients than in those with severe HA, the ...

To the Editor:—Recombinant1 factor VIIa has recently been developed to reduce bleeding complications in hemophilic patients. After injury to the vessel wall, tissue factor (TF) is exposed to the circulating blood and forms complexes with already activated FVII (FVIIa). The complex TF-FVIIa initiates hemostasis at the site of injury by activating FX into FXa, thereby providing the first amount o...

Introduction Acquired haemophilia A (AHA) is a rare but clinically relevant bleeding disorder due to autoantibodies (inhibitors) against coagulation factor VIII (FVIII)1-3. AHA is usually triggered by infections, malignancies, autoimmune diseases, or pregnancy. Some cases associated with drug intake have also been described, but about half of cases remain unexplained and are classified as "idio...

See related article, pages 307–312. The Intensive Blood Pressure Reduction In Acute Cerebral Hemorrhage Trial (INTERACT) trial suggests that early, intensive blood pressure (BP) lowering can attenuate hematoma extension or growth (HE) 24 hours after intracerebral hemorrhage (ICH).1 The primary goal of this more detailed analysis published in this issue of Stroke2 is to determine if the BP-lower...

Readers of my column know that I am a founding member of the Thomas Jef ferson University Hospital Pharmacoeconomics and Cost Effectiveness (PEACE) Committee (see “Give PEACE a Chance” in the April 2005 issue of P&T). I am also approaching my 20th anniversary at Jefferson, a milestone of which I am quite proud. This occasion and my membership on the PEACE committee recently came together for me...

http://dx.doi.org/10.1160/TH16-02-0116 Thromb Haemost 2016; 116: 201–203 Dear Sirs, Considering the high quality of replacement therapy available nowadays for haemophiliacs, the most challenging complication of haemophilia is currently the development of inhibitors, which render replacement therapy ineffective, preclude the access of patients to a safe and effective standard of care (particular...

Acquired factor VIII (FVIII) inhibitors can cause life-threatening bleeding. Rapid restoration of coagulation is vital. Therapeutic approaches include factor substitution,1,2 immunosuppression (eg, steroids, cyclophosphamide3), and plasmapheresis.4 A novel treatment option is rituximab, a chimeric monoclonal antibody targeting the CD20 antigen and blocking proliferation of normal B cells.5 Rece...